Evidence map›Paper›PMID 40770137›Full record

ArticleEuropean radiology2026

Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).

Natasha Thorley, Tom Parry, Francesco Giganti, Douglas Kopcke, Harbir S Sidhu, Giorgio Brembilla, Emma Stallard, Mark Emberton, Caroline M Moore, Shonit Punwani and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Natasha ThorleyCentre for Medical Imaging, University College London, London, UK. natasha.thorley@ucl.ac.uk.ORCID http://orcid.org/0000-0001-8928-895X
Tom ParryCentre for Medical Imaging, University College London, London, UK.
Francesco GigantiDepartment of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Douglas KopckeDepartment of Radiology, North Bristol NHS Trust, Bristol, UK.
Harbir S SidhuCentre for Medical Imaging, University College London, London, UK.
Giorgio BrembillaCentre for Medical Imaging, University College London, London, UK.
Emma StallardCentre for Medical Imaging, University College London, London, UK.
Mark EmbertonDivision of Surgical and Interventional Science, University College London, London, UK.
Caroline M MooreDivision of Surgical and Interventional Science, University College London, London, UK.
Shonit PunwaniCentre for Medical Imaging, University College London, London, UK.
ReIMAGINE Study Group

Funding

Medical Research Council MR/R014043/1
6 · The paper itself

Abstract

objectivesTo evaluate the diagnostic accuracy and imaging findings of an abbreviated biparametric MRI (bpMRI) protocol for prostate cancer (PCa) screening. MATERIALS AND

methodsIn this single-centre, prospective study, men aged 50-75 years were randomly selected for invitation to screening through participating general practices. Participants underwent screening with abbreviated bpMRI (axial T2-weighted and b2000 diffusion-weighted sequences) and PSA testing between October 2019 and December 2020. Screening MRIs were independently reported by two radiologists as either positive or negative by screening criteria, with a third radiologist if there was disagreement. Positive MRI or raised PSA density (PSAd) (≥ 0.12 ng/mL

resultsAmong 303 men who completed screening (median age 62 years [IQR 56, 68]), 16% (48/303) had a positive screening MRI, and an additional 5% (16/303) had raised PSAd alone. Of 61 men referred to secondary care, 48% (29/61) had clinically significant PCa, with 2 (3%, 2/61) additional diagnoses during 2-year follow-up. Of 31 men with clinically significant PCa, 87% (27/31) had a positive screening MRI and 42% (13/31) had raised PSAd. The PPV of the screening MRI was 59% (27/46, 95% CI: 44, 72).

conclusionAbbreviated bpMRI may have value in PCa screening independently of PSA testing. However, prospective multicentre evaluation is needed to assess the feasibility and cost-effectiveness of MRI-based screening at a national level. KEY POINTS: Question MRI may reduce over- and under-diagnosis from prostate-specific antigen (PSA) testing in PCa screening, but its use is limited by long scan times, cost, and availability. Findings Abbreviated bpMRI identified more men with clinically significant cancer than PSAd (≥ 0.12 ng/mL

Indexed as

Early Detection of CancerMagnetic Resonance ImagingProstatic NeoplasmsAgedFeasibility StudiesHumansMaleMiddle AgedProspective StudiesProstate-Specific AntigenReproducibility of ResultsSensitivity and SpecificityProstate-Specific AntigenBiparametricMagnetic resonance imagingProstateProstate cancerScreening

Identifiers

PMID40770137
PMCPMC12963090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.